Thanks to Tall Allen I have read some solid studies that say combining treatments is best for overall survival, for personal reasons I am on 150 Bicalutimide monotherapy, these reasons were a severe loss of strength which I thought maybe it was because of previous hormone therapy, in reality it was IBM muscle disease. Using Bicalutimide I hope I can keep strength going longer.
I post the numbers for interest sake on effect of Bicalutimide for now I am going with Monotherapy, when it fails I hope the other methods will work and give extra time. I am not aware of a study that investigated mono therapy for example start with Bicalutimide then Zoladex, then add Zytiga, next Xtandi or some formula like this. The ones I saw all start with hormone therapy and then add something else. So anything where you start with Zytiga first or Xtandi holding Lupron for last.
I know Magnus 1964 has had success when on mono, I think mono Bicalutimide Is popular in Europe if anyone knows of studies sequencing one at a time please let me know.
The other question I have is last summer I had 3 bone Mets treated by SABR, my testosterone is slowly rising now on Bicalutimide but PSA low, does Bicalutimide work as well as Zoladex on bone Mets if PSA is undetectable. If no PSA can bone Mets grow. If bone Mets grow would this not cause PSA to rise.
June 2020 under .008. .2020-06-23 10:09 AM
Ga <0.008<4.5
2020-03-12 12:01 PM0.012<4.5
2019-12-15 09:58 AM0.032<4.5
2019-10-21 11:08 AM0.048<4.5
2019-07-29 02:09 PM0.083<4.5
2019-04-26 08:56 AM0.26<4.5
2019-01-17 11:03 AM6.6<4.5
I went on Bicalutimide in February 2019, but when 3 bone metastases were discovered went to Zoladex in May, then back to Bicalutimide in December. .008 is pretty neat, hopefully I get some time,